Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Research Foundation, Cincinnati, OH.
Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark; and.
Blood Adv. 2018 Nov 27;2(22):3126-3136. doi: 10.1182/bloodadvances.2018024851.
Plasminogen deficiency is associated with severely compromised fibrinolysis and extravascular deposition of fibrin. In contrast, coagulation factor VIII (FVIII) deficiency leads to prolonged and excessive bleeding. Based on opposing biological functions of plasminogen and FVIII deficiencies, we hypothesized that genetic elimination of FVIII would alleviate the systemic formation of fibrin deposits associated with plasminogen deficiency and, in turn, elimination of plasminogen would limit bleeding symptoms associated with FVIII deficiency. Mice with single and combined deficiencies of FVIII (F8) and plasminogen (Plg) were evaluated for phenotypic characteristics of plasminogen deficiency, including wasting disease, shortened lifespan, rectal prolapse, and multiorgan fibrin deposition. Conversely, to specifically examine the role of plasmin-mediated fibrinolysis on bleeding caused by FVIII deficiency, F8 and F8/Plg mice were subjected to a bleeding challenge. Mice with a combined deficiency in FVIII and plasminogen displayed no phenotypic differences relative to mice with single FVIII or plasminogen deficiency. Plg and F8/Plg mice exhibited the same penetrance and severity of wasting disease, rectal prolapse, extravascular fibrin deposits, and reduced viability. Furthermore, following a tail vein-bleeding challenge, no significant differences in bleeding times or total blood loss could be detected between F8 and F8/Plg mice. Moreover, F8 and F8/Plg mice responded similarly to recombinant FVIII (rFVIII) therapy. In summary, the pathological phenotype of Plg mice developed independently of FVIII-dependent coagulation, and elimination of plasmin-driven fibrinolysis did not play a significant role in a nonmucosal bleeding model in hemophilia A mice.
纤溶酶原缺乏与严重的纤维蛋白溶解受损和血管外纤维蛋白沉积有关。相比之下,凝血因子 VIII(FVIII)缺乏会导致延长和过度出血。基于纤溶酶原和 FVIII 缺乏的相反生物学功能,我们假设 FVIII 的基因缺失将减轻与纤溶酶原缺乏相关的全身纤维蛋白沉积的形成,反过来,纤溶酶原的消除将限制与 FVIII 缺乏相关的出血症状。评估了 FVIII(F8)和纤溶酶原(Plg)单一和联合缺乏的小鼠的纤溶酶原缺乏表型特征,包括消瘦病、寿命缩短、直肠脱垂和多器官纤维蛋白沉积。相反,为了专门研究纤溶介导的纤维蛋白溶解对 FVIII 缺乏引起的出血的作用,对 F8 和 F8/Plg 小鼠进行了出血挑战。与单一 FVIII 或纤溶酶原缺乏的小鼠相比,F8 和 F8/Plg 小鼠的联合缺乏没有表现出表型差异。Plg 和 F8/Plg 小鼠表现出相同的消瘦病、直肠脱垂、血管外纤维蛋白沉积和存活率降低的易感性和严重程度。此外,在尾静脉出血挑战后,无法检测到 F8 和 F8/Plg 小鼠之间出血时间或总失血量的显著差异。此外,F8 和 F8/Plg 小鼠对重组 FVIII(rFVIII)治疗的反应相似。总之,Plg 小鼠的病理表型独立于 FVIII 依赖性凝血发展,纤溶酶驱动的纤维蛋白溶解的消除在 A 型血友病小鼠的非黏膜出血模型中没有发挥重要作用。